Last reviewed · How we verify
Tacrolimus targeted plain dose
Tacrolimus targeted plain dose is a marketed immunosuppressive drug developed by University Hospital, Tours, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and well-documented efficacy in preventing organ rejection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Tacrolimus targeted plain dose |
|---|---|
| Also known as | Advagraf® |
| Sponsor | University Hospital, Tours |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) (PHASE4)
- Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |